Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
Firm Expects To Scale Up Rare Diseases Unit And Generics Going Forward
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
You may also be interested in...
ANI Plans To Shutter Oakville Plant By Q1 2023
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.
ANI Expects Growth From Launches And Novitium Integration
ANI Pharma has outlined key pillars of its strategy to drive growth in the coming quarters as the company reported a slight increase in revenues in the fourth quarter of 2021. The company’s recent purified Cortrophin Gel launch is off to a good start, as ANI leadership counts on its commercial longevity.